Press Releases

    • OCT 28 2020

    Oncoceutics Begins Clinical Trial with Next-Generation Imipridone ONC206 at the NIH

    Philadelphia, PA (October 28, 2020) – Oncoceutics, Inc. announced today that the first patient has been treated in a first-in-human clinical trial of the company’s next-generation imipridone ONC206 at the National Institutes of Health (“NIH”). The Phase I trial, for adults with recurrent primary central nervous system (CNS) neoplasms, is led by Mark Gilbert, MD,

    • OCT 12 2020

    Oncoceutics Expands IP Portfolio With Additional Patents for ONC201 and ONC212

    Philadelphia, PA (October 12, 2020) – Oncoceutics, Inc. announced that the European Patent Office has issued a Decision to Grant for a Composition of Matter patent for ONC212, one of the company’s next-generation oncology drug candidates. The company also announced that a pending ONC201 patent has been granted for Mexico and that it received a

    • JUL 24 2020

    FDA Grants Rare Pediatric Disease Designation to ONC201 for the Treatment of H3 K27M-Mutant Glioma

    Philadelphia, PA (July 21, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Oncoceutics’ investigational cancer drug ONC201 for the treatment of “H3 K27M-mutant glioma”. The Rare Pediatric Disease Priority Review Voucher program, which was created as

    • JUL 22 2020

    Oncoceutics Commemorates GBM Awareness Day

    Philadelphia, PA (July 22, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates GBM Awareness Day this July and expresses its support for all those affected by this devastating form of brain cancer. Glioblastoma (GBM) is the most common type of malignant brain tumor among adults and is typically fatal.  The two-year survival